Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Apr 2, 2009

Beckman Coulter to Pay Clinical Data $17M for Genomic Services Division

  • Beckman Coulter will take over Clinical Data’s Cogenics division for approximately $17 million. Cogenics provides genomics services and has operations in the U.S., U.K., Germany, and France.

    Under terms of the agreement, Clinical Data will receive approximately $15.4 million at the closing, which is expected in April. In addition, it expects to retain approximately $2 million in cash from Cogenics immediately prior to the sale.

    Beckman Coulter points out that the acquisition complements the Agencourt Biosciences business and expands its reach into new territories. Cogenics’ solutions span current and next-generation sequencing, gene expression, clinical and nonclinical genotyping, biomanufacturing support, nucleic acid extraction, as well as biobanking for both research and regulated environments.

    Clinical Data notes that this agreement completes its efforts to monetize noncore assets and focus resources on advancing its therapeutics pipeline. The company expects data from the Phase III evaluation of vilazodone in depression during the second quarter. Additionally, it plans to move Stedivaze, a pharmacologic stress agent for myocardial perfusion imaging, into late-stage testing  this year.

    Clinical Data obtained Stedivaze and reportedly other preclinical and clinical compounds in cardiology, diabetes, inflammatory diseases, and sickle cell anemia through its acquisition of Adenosine Therapeutics for $11 million.



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »